[Pubmed] Addressing Outcome Measure Variability in Myasthenia Gravis Clinical Trials

[RSS-Bot]

Neurology. 2023 Apr 19:10.1212/WNL.0000000000207278. doi: 10.1212/WNL.0000000000207278. Online ahead of print.

ABSTRACT

An increasing number of clinical trials are enrolling patients with myasthenia gravis (MG). A lack of standardization in the performance of outcome measures leads to confusion amongst site research teams and is a source of variability in clinical trial data. MGNet, the NIH-supported Rare Disease Clinical Research Network for MG, views standardization of MG outcome measures as a critical need. To address this issue, a group of experts summarized key outcome measures used in MG clinical trials and a symposium was convened to address issues contributing to outcome measure variability. Consensus recommendations resulted in changes to outcome measure instructions, and in some cases, modifications to specific instruments. Recommended changes were posted for public commentary prior to finalization. Changes to the MG-Activities of Daily Living, MG-Quality of Life-15r, and MG-Impairment Index were limited to adding details to the administration instructions. Recommendations for proper positioning of subjects and how to score items that could not be performed due to non-MG reasons were provided for the MG Composite. The Quantitative MG (QMG) Score required the most attention, and changes were made both to the instructions and the performance of certain items resulting in the QMG-Revised (QMG-R). The Post-Intervention Status was felt to have a limited role in clinical trials, except for the concept of minimal manifestation status. As a next step training materials and revised source documents, which will be freely available to study teams, will be created and posted on the MGNet website. Further studies are needed to validate changes made to the QMG-R.

PMID:37076302 | DOI:10.1212/WNL.0000000000207278


Source: https://pubmed.ncbi.nlm.nih.gov/3707630 ... t6+86293ac